1. ATAC Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002, 359: 2131-2139. 10.1016/S0140-6736(02)09088-8.
2. International Breast Cancer Study Group: [ http://www.ibcsg.org/pps/SOFT-TEXT-PERCHE_slides-Oct02.ppt ]
3. Albain K, Green S, Osborne K, Cobau C, Levine E, Ingle J, Pritchard K, Schneider J, O'Sullivan J, Hess E, Martino S: Tamoxifen (T) versus cyclophosphamide, adriamycin and 5-FU plus either concurrent of sequential T in postmenopausal, receptor(+), node(+) breast cancer: a Southwest Oncology Group phase III intergroup trial (SWOG-INT-0100) [abstract]. Proc Am Soc Clin Oncol. 8814, 450: 128a-
4. Henderson IC, Berry D, Demetri G, Cirrincione G, Goldstein L, Martino S, Ingle JN, Cooper MR, Canellos G, Borden E, Fleming G, Holland JF, Graziano S, Carpenter J, Muss H, Norton L: Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer [abstract]. Proc Am Soc Clin Oncol. 1998, 17: 101a-
5. French Adjuvant Study Group: Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 Randomized Trial. J Clin Oncol. 2001, 19: 602-611.